NELIPEPIMUT-S ACETATE
Breast Cancer With Low to Intermediate HER2 Expression
Galena Biopharma, Inc.vaccinePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Breast Cancer With Low to Intermediate HER2 Expression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf, Sargramostim Galena Biopharma, Inc. | Phase 3 | BB |
Same molecule, other indications
NELIPEPIMUT-S ACETATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →